Salute e Benessere

Lecanemab named one of the world's best inventions in 2023 by TIME

Gunilla Osswald, CEO of BioArctic:"It is a great honor and tremendous recognition that lecanemab is included in TIME's list of the world's best inventions this year. It feels fantastic that we are part of driving the paradigm shift currently happening globally in the treatment of Alzheimer's disease." Gunilla Osswald, CEO of BioArctic: "It is a great honor and tremendous recognition that lecanemab is included in TIME's list of the world's best inventions this year. It feels…
PR Newswire
24/10/2023

Quotient Sciences Announces Major Investment in Sterile Fill/Finish Capacity in…

This latest investment provides a major boost to the Alnwick facility, increasing the number of Grade C cleanrooms from one to three. This latest investment provides a major boost to the Alnwick facility, increasing the number of Grade C cleanrooms from one to three. As part of this expansion, the company has invested in a new isolator technology, enabling larger batch sizes and reduced cycle times per manufacturing campaign. The site also benefits from an integrated in-house microbiology...
PR Newswire
24/10/2023

Wolters Kluwer Applauded by Frost & Sullivan for Improving Healthcare…

Gain deeper insights into what distinguishes Wolters Kluwer as a Competitive Strategy Leader in the global conversational artificial intelligence (AI) healthcare industry. Gain deeper insights into what distinguishes Wolters Kluweras a Competitive Strategy Leader in the global conversational artificial intelligence (AI) healthcare industry. Wolters Kluwer'sEmmi leverages conversational AI to enable patients to be a participant in their health care while reducing the burden on the...
PR Newswire
24/10/2023

King Faisal Specialist Hospital and Research Centre Announces Innovative…

Enhances Drug Effectiveness and Patient Safety KFSH&RC's experts have said that this analysis empowers physicians to prescribe medications customized to each patient, factoring in their unique health conditions and genetic traits. Patients' responses to pharmaceuticals can significantly differ based on their genetic profiles. As a result, what proves effective for one patient may have minimal impact in another. It is worth noting that statistics reveal that 15% of hospital admissions...
Nasdaq GlobeNewswire
24/10/2023

Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness…

A report from Taylor & Francis said: "It appears increasingly clear that approaching AML as a homogenous disease entity is unsatisfactory in view of the variations in such disease factors as cytogenetic and molecular markers, age, and disease severity at presentation; all of which contribute significantly to heterogeneity of the disease. Moving forward, treating AML would likely require tailored therapy following advances in technology such as molecular profiling, drug sensitivity and…
PR Newswire
24/10/2023

Nexstim Plc: Composition of the Shareholders' Nomination Committee

Company Announcement, Helsinki, 24 October 2023 at 3 PM (EEST) Nexstim Plc: Composition of the Shareholders' Nomination Committee Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces the composition of the Shareholders' Nomination Committee.Leena Niemistö, Chair of the Board of Nexstim and representative of the Company's largest shareholder, continues to chair the Nomination Committee. Ossi Haapaniemi, and Kyösti Kakkonen as a representative of Joensuun Kauppa ja Kone…
Nasdaq GlobeNewswire
24/10/2023

ITM Reports on Participation at 3rd ICPO Forum for Theranostics in Precision…

Garching / Munich, Germany, October 24, 2023 – ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, today reported on its participation at the 3 rd International Centers for Precision Oncology (ICPO) Forum for Theranostics in Precision Oncology which took place in Garching near Munich, Germany, from October 12-13, 2023. The company also announced support for the ICPO's newly established Academy for Theranostics, which was unveiled as part of the...
Nasdaq GlobeNewswire
24/10/2023

uniQure Announces Major Presence at the European Society of Gene and Cell…

uniQure N.V.(NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that 12 data presentations, including two oral presentations, will be delivered at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting being held October 24-27 in Brussels, Belgium. “Our multiple presentations at ESGCT demonstrate uniQure's continued leadership in advancing important research within the field of gene...
Nasdaq GlobeNewswire
24/10/2023

Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation…

RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous and uveal melanoma, ovarian cancer and other cancer typesRegulatory activities underway with an initial focus on a registration-directed trial in melanoma as step one to leverage the full breadth of PRAME Houston, Texas and Tuebingen, Germany , October 24, 2023–Immatics N.V.(NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the...
Nasdaq GlobeNewswire
24/10/2023

ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on…

To access the conference call, please registerhere. Registrants will receive the dial-in number and unique PIN. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under “Events and Presentations” in the Investors section of the ADC Therapeutics website atir.adctherapeutics.com. The archived webcast will be available for 30 days following the call. About ADC Therapeutics ADC Therapeutics...
Nasdaq GlobeNewswire
24/10/2023

Aktiia SA collaborates on landmark study led by McMaster University, the Private…

Recognized as one of the foremost authorities in their respective fields, Professors David Conen at McMaster University and Lorenz Risch at the Private University of Liechtenstein and the Dr. Risch Laboratory have led the GAPP study since its launch in 2010 with a wealth of expertise and experience. Thanks to its highly qualified clinical site staff, the GAPP study has enabled to collect millions of data subjects and has already generated dozens of notable publications, contributing…
PR Newswire
24/10/2023

Moringa Extract Market to Reach US$ 4,986.4 Million by 2033 Due to Rising…

The moringa extract market is expected to expand from US$ 1,243.6 million in 2023 toUS$ 4,986.4 million by 2033. Between 2023 and 2033, sales will likely soar at 14.9% CAGR. The moringa extract market is expected to expand fromUS$ 1,243.6 millionin 2023 to US$ 4,986.4 millionby 2033. Between 2023 and 2033, sales will likely soar at 14.9% CAGR. Get The Sample PDF Summary to obtain an overview of the Comprehensive Research Report.The sample is available here ! ...
PR Newswire
24/10/2023

Professor Sir Munir Pirmohamed Appointed as Chair of Prix Galien UK Committee

Upon his appointment, Professor Sir Munir stated, "I am honored to take on the role of Chair of the Prix Galien UK Committee. I believe that innovation in healthcare, pharmaceuticals and digital technologies is essential to improving human health, and I am committed to upholding the legacy of this prestigious award." Upon his appointment, Professor Sir Munir stated, "I am honored to take on the role of Chair of the Prix Galien UK Committee. I believe that innovation in…
PR Newswire
24/10/2023

Invizius Announces Appointment of World-Renowned Nephrologist Professor Bernard…

Invizius is developing its novel, complement regulation biotechnology into breakthrough treatments for patients on dialysis, to improve the poor patient outcomes that have persisted for decades. Its lead product, H-Guard®, is for Haemodialysis and is designed to preserve renal function and cardiovascular health and improve patients' Quality of Life. By taking a precision medicine approach, treatment will target patients at highest risk of life-threatening complications. Invizius is developing...
PR Newswire
24/10/2023

Clinical Trial Application (IND) for BioRay Pharmaceutical's BR105 Injection…

The efficacy of targeting CD47/SIRPα has been validated in various tumor models, and previous clinical studies suggest that targeting the CD47/SIRPα signaling pathway may have a broad spectrum of anti-tumor activity. CD47/SIRPα-targeted therapy has shown positive results in acute myeloid leukemia, lymphoma, head and neck squamous cell carcinoma, gastric cancer, and other malignancies. The efficacy of targeting CD47/SIRPα has been validated in various tumor models, and previous clinical…
PR Newswire
24/10/2023

Astraveus awarded €10.4 million grant by the French government as part of France…

This non-dilutive funding closely follows the #FrenchTech2030 accreditation led by the Secrétariat Général Pour l'Investissement ("SGPI)", building upon the ongoing support received from the French and European innovation ecosystem, and the recent closure of an oversubscribed €16.5 million seed financing round. This non-dilutive funding closely follows the #FrenchTech2030 accreditation led by the Secrétariat Général Pour l'Investissement ("SGPI)", building upon the ongoing…
PR Newswire
24/10/2023

BioWorld by Clarivate Examines Impact of Emerging Medicines on Obesity

The increasing prevalence of obesity across the world is driving interest among investors to be a part of a movement that is poised to change the health care paradigm. Emerging medicines including glucagon-like peptide 1 (GLP-1) receptor agonists and drugs with other mechanisms of action are increasingly shown to have benefits beyond weight loss. The increasing prevalence of obesity across the world is driving interest among investors to be a part of a movement that is poised to change the...
PR Newswire
24/10/2023

The dental and medicinal benefits board, TLV, has decided on 19 October that…

"At Accord, we work to develop new treatment options that meet the needs of patients and healthcare, where Orgovyx is a good example that benefits both parties, with reduced side effects and a more comfortable administration for patients and it releases resources for the healthcare system when no injections are needed ." says Jan Stenfors, medical & scientific advisor for the Nordics and Baltics. " At Accord, we work to develop new treatment options that meet the needs of…
PR Newswire
24/10/2023

Sandoz reports year-to-date sales for the first nine months of 2023

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Nine-month net sales 1of USD 7.1 billion, up 6 percent in constant currencies (cc) (1) Solid performance in Generics; Biosimilars grow double-digits Recent strategic milestones include US Hyrimoz ®launch, approval of Tyruko ®in US and Europe, partnership on ustekinumab and closing of Mycamine ®acquisitionFull-year 2023 guidance confirmed Sandoz successfully listed on SIX Swiss Exchange as independent...
Nasdaq GlobeNewswire
24/10/2023

Hyloris Announces Out-Licensing of Atomoxetine Oral Liquid in Canada

Territorial expansion for a product candidate previously exclusively targeting the U.S.Kye Pharmaceuticals to register and commercialize in CanadaLiège, Belgium – 24 October 2023 – 7AM CET – Non-regulated information - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL),a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces it has out-licensed its product candidate atomoxetine oral liquid for the treatment of...
Nasdaq GlobeNewswire
24/10/2023

Novartis delivers 12% sales and 21% core operating income growth from continuing…

Ad hoc announcement pursuant to Art. 53 LR Transformation into a “pure-play” innovative medicines business is complete, with thespin-off of Sandoz ;commentary below is on continuing operations 2 Q3 sales grew +12% (cc, +12% USD) with core operating income growing +21% (cc, +17% USD) Growth driven by continued strong performance fromKesimpta(+124% cc),Entresto(+31% cc),Kisqali(+76% cc),Pluvicto(+217% cc) andScemblix(+157% cc) Q3 operating income grew...
Nasdaq GlobeNewswire
24/10/2023

Idorsia announces financial results for the first nine months of 2023 – adapting…

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – October 24, 2023Idorsia Ltd (SIX: IDIA) today announced its financial results for the first nine months of 2023. Business highlights Transaction withSosei Heptares(hereafter referred as the “Sosei Deal”) :Idorsia sold its Asia Pacific (ex-China) operations on July 20 – including selected license rights to products – for a total consideration of CHF 400 million. Cost reduction initiativetargeting a...
Nasdaq GlobeNewswire
24/10/2023

OBiO Announces Strategic Partnership with Refreshgene to Realize…

Driven by human genetics and translational medicine, Refreshgene develops new gene therapy and drugs to satisfy unmet clinical needs via highly druggable and tissue-specific gene delivery technology. Refreshgene owns well-established research and technology system of AAV gene therapy and built up clinic-stage pipeline in the field of retinal diseases and congenital deafness. Moreover, Refreshgene is the first gene therapy company in the world to apply dual AAV vector technology into clinical…
PR Newswire
24/10/2023

Singapore-based Juniper Biologics Awarded the Most Innovative Oncology…

Juniper Biologics was founded with a vision to transform the landscape of healthcare by introducing novel therapies designed to address unmet medical needs. The company's primary areas of focus are Oncology and Oncology Supportive Care, Rare/Orphan Diseases, and Gene Therapy. With an unwavering dedication to improving the lives of patients around the world, Juniper Biologics has garnered acclaim for its innovative approach to pharmaceuticals and its leadership in bringing cutting-edge treatments…
PR Newswire
24/10/2023
Altri  Comunicati